Merz Aesthetics Announces the Launch of Ultherapy PRIME Platform as the Next Generation of Nonsurgical Skin Lifting Treatments
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of Ultherapy PRIME – a noninvasive treatment that provides a truly personalized and long-lasting* lift of the skin in one session with zero downtime.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240923820281/en/
Merz Aesthetics Announces the Launch of Ultherapy PRIME Platform as the Next Generation of Nonsurgical Skin Lifting Treatments (Photo: Business Wire)
The Ultherapy PRIME platform is the evolution of Ultherapy®, which has been recognized as the Gold Standard for nonsurgical lifting and skin tightening due to its large body of clinical evidence, well-established mechanism of action (MOA) and high patient satisfaction.1,2,3 Built on a legacy of proven, natural-looking outcomes, Ultherapy PRIME redefines the future of non-invasive skin lifting and tightening by uniquely combining advanced ultrasound technology, vivid real-time imaging and proven results. These advancements promote long-lasting* results paired with healthier-looking skin.1,2,3,4,5
The platform features a modern design with an advanced operating system, delivering 10x faster processing power, elevated ergonomics and seamless workflows for aesthetic health care professionals. Additionally, with a 35% larger screen and brighter, crisp images from all angles, Ultherapy PRIME offers a vivid visualization experience for a truly personalized, long-lasting* lift patients can see.**
“The launch of Ultherapy PRIME demonstrates our commitment to persist in innovation,” said Bob Rhatigan, CEO, Merz Aesthetics. “As the leader in noninvasive lifting, we’re excited to bring Ultherapy PRIME to our customers as the next generation, premier platform and as a proven technology*** and customizable, long-lasting* treatment option.”
Ultherapy PRIME’s unique technology with real-time visualization goes beyond other noninvasive treatments to target the right collagen and elastin-rich layers of the tissue at multiple depths, delivering consistent and precise energy where the patient needs it the most.1,2,3,4,6,7 Ultherapy PRIME’s mechanism of action allows for personalized skin lifting outcomes through collagen and elastin stimulation, which can last up to a year or more.1,2,3,4,6,7 It is a great treatment option for all skin types and skin tones to maintain a youthful, healthy appearance in just one session with zero downtime.1
With three million Ultherapy treatments performed around the world, Ultherapy PRIME builds on an impressive legacy of lifts of the skin on the brows, area under the chin and neck and improves lines and wrinkles on the décolleté.1,2,3 With Ultherapy’s 95% patient satisfaction at year one and one of the strongest clinical bodies of evidence cited in over 120 publications and 56 clinical studies,2,4 Ultherapy PRIME is built on a legacy of safe and effective treatments. Ultherapy PRIME is The Lift You Can SEE.
“Now more than ever, patients seek treatments tailored to their unique skin needs. This is why Ultherapy is a cornerstone of my practice,” said world-renowned, board-certified dermatologist Sabrina Fabi, MD. “The new Ultherapy PRIME platform offers all the signature benefits of Ultherapy for noninvasive, long-lasting* lifting, now with significant advancements. Ultherapy PRIME improves the quality of the skin, catering to diverse patient needs with all skin types seeking a noninvasive lift and a younger, healthier appearance in just one session and no downtime.”
To learn more about Ultherapy PRIME, visit Ultherapy.com and follow @Ultherapy on Instagram.
*results can last up to a year or more 1,4
** in comparison to the previous version
***based on clinical studies conducted with Ultherapy legacy device
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
About Ultherapy®:
The noninvasive Ultherapy® procedure is intended for dermatological sculpting and lifting of the dermis on the upper face, lower face, neck and décolleté. The most common side effects reported in clinical trials were redness, swelling, pain and transient nerve effects. Reported adverse events from post-marketing surveillance are available in the Instructions for Use (IFU). Please see the IFU for product information.
References:
- Ulthera® Instructions for Use
- Fabi SG, Joseph J, Sevi J, Green JB, Peterson JD. Optimizing patient outcomes by customizing treatment with microfocused ultrasound with visualization: gold standard consensus guidelines from an expert panel. J Drugs Dermatol. 2019;18(5):426-432.
- Park JY, et al. Customized Treatment Using Microfocused Ultrasound with Visualization for Optimized Patient Outcomes: A Review of Skin tightening Energy Technologies and a Pan-Asian Adaptation of the Expert Panel’s Gold Standard Consensus. J Clin Aesthet Dermatol. 2021;14(5): E70-E79.
- Werschler WP, Werschler PS. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;9(2):27-33.
- Goldie K, Kerscher M, Fabi SG, Hirano C, Landau M, Lim TS, Woolery-Lloyd H, Mariwalla K, Park JY, Yutskovskaya Y. Skin Quality - A Holistic 360° View: Consensus Results. Clin Cosmet Investig Dermatol. 2021 Jun 14;14:643-654. doi: 10.2147/CCID.S309374. PMID: 34163203; PMCID: PMC8214518.
- Sasaki G, Grossman J, Fabi SG, et al. Stimulation of Collagen Synthesis in Human Skin Following Microfocused Ultrasound Therapy. Presented at the ASDS 2018 Annual Meeting.
- White WM, Makin IR, Barthe PG, Slayton MN, Gliklich RE. Selective creation of thermal injury zones in the superficial musculoaponeurotic system using intense ultrasound therapy: a new target for non-invasive facial rejuvenation. Arch Facial Plast Surg. 2007;9(1):22-29.
© 2024 Merz North America, Inc., Merz, and Merz Aesthetics are trademarks or registered trademarks of Merz Pharma GmbH & Co. KGaA in the EU and/or certain other countries. Ultherapy, Ulthera are trademarks and/or registered trademarks of Ulthera, Inc. in the EU and/or certain other countries. Various features of the ULTHERA® System are covered by U.S. patents identified at https://merzaesthetics.com/patents/. Other U.S. and International patents to which Ulthera, Inc. has rights are issued, published, or pending.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240923820281/en/
Contacts
Emily Browder
Head of Global Communications
6501 Six Forks Road Raleigh NC 27615
919-302-3296
media@merz.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9% 15.6% -241 bps -306 bps Net income attributable to SLB - GAAP basis $797 $1,095 $1,068 -27% -25% Diluted EPS - GAAP basis $0.58 $0.77 $0.74 -25% -22% Adjusted EBITDA* $2,020 $2,382 $2,057 -15% -2% Adjusted EBITDA margin* 23.8% 25.7% 23.6% -186 bps 18 bps Pretax segment operating income* $1,556 $1,918 $1,649 -19% -6% Pretax segment operating margin* 18.3% 20.7% 18.9% -232 bps -60 bps Net income attributable to SLB, excluding charges &
Corona, The World’s Most Valuable Beer Brand 1 , Announces Its 100-Year Anniversary with Global Celebration25.4.2025 11:00:00 EEST | Press release
Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive list of the top 100 beaches in the world to visit, and a signed multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro — all offering people across the globe opportunities to connect with their beach side. “For 100 years, Corona has
Ant Group Unveils New Recruitment Initiative for Top AI Talents, Ramping Up AI Innovation Efforts25.4.2025 10:28:00 EEST | Press release
Ant Group today unveiled Plan A, a new recruitment initiative to attract top artificial intelligence researchers, reinforcing its commitment to accelerating AI research and development under the “AI First” corporate strategy. Operating within the framework of Ant Star—Ant Group’s year-round campus recruitment program—Plan A specifically targets AI talents who are ambitious, adaptable, altruistic, and analytical. Outstanding graduates from universities worldwide with STEM majors are encouraged to apply for Plan A. Relevant fields include computer science, software engineering, artificial intelligence, cybersecurity, information and telecommunication engineering, mathematics, statistics, and other emerging interdisciplinary areas. To better foster the development of technological innovators in this new AI era, Plan A offers candidates comprehensive support and resources, including unrestricted access to AI hardware and tailored career paths that allow for significant research freedom. Ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom